Results 261 to 270 of about 10,477,560 (323)

Discussion on the Radiation Treatment of Cancer of the Antrum and Ethmoid [PDF]

, 1957
Margaret D. Snelling
openalex   +1 more source

In Response to "Photosensitizing Drugs and Risk of Skin Cancer in Women-A Prospective Population-Based Study". [PDF]

Photodermatol Photoimmunol Photomed
Birrell SN.
europepmc   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

CANCER OF THE THYROID AND ITS PRESENT-DAY TREATMENT

, 1925
Lloyd F. Craver
openalex   +2 more sources

Determinants and barriers to women's participation in breast cancer screening activities in Jordan: an in-depth study. [PDF]

BMC Public Health
Albadawi RS, Alsharawneh A, Othman EH.
europepmc   +1 more source

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

The Impact of Malignancy on the Risk of Venous Thromboembolism in Pregnant Women: A Systematic Review. [PDF]

Health Sci Rep
Vaezi A, Rafiei SKS, Amiri B, Rezvanimehr A, Naji Abhary M, Mahdavi P, Abbasalizadeh M, Yavari G, Sattari MS, Kheirandish A, Erabi G, Zadeh FV, Rasekh F, Pormehr-Yabandeh A, Mohagheghi SZ, Zaraj H, Abdi A, Dadkhah PA, Deravi N.   +18 more
europepmc   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Enhancing clinical outcome predictions through effective sample size evaluation in graph-based digital twin modeling. [PDF]

BioData Min
Li X, Chang JH, Venkatesan M, Wang ZP, Moore JH.   +4 more
europepmc   +1 more source

Microglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis

Molecular Oncology, EarlyView.
Microglia act as tumor suppressors during brain metastasis colonization but shift to a tumor‐promoting role after melanoma brain metastases form. NF‐κB/RelA signaling emerges as a key driver of this phenotypic shift. Targeting this pathway reprograms microglia into a pro‐inflammatory state, enhancing antitumor immunity and immune checkpoint inhibitor ...
Noam Savion‐Gaiger, Dorin Bar‐Ziv, Harriet Kluger   +2 more
wiley   +1 more source